{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Withdrawn" in comments (approximate match)
Status:
Investigational
Source:
NCT02394028: Phase 3 Interventional Completed Crohn Disease
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02488330: Phase 3 Interventional Completed Solid Tumor
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02326740: Phase 3 Interventional Terminated Pyoderma Gangrenosum
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00104078: Phase 1/Phase 2 Interventional Completed Becker Muscular Dystrophy
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00103558: Phase 1/Phase 2 Interventional Completed Chronic Lymphocytic Leukemia
(2004)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01665391: Phase 2 Interventional Completed Primary Focal Segmental Glomerulosclerosis
(2012)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:39689
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:535816
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:269908
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:270308
Source URL:
Class:
PROTEIN
